Lymphocyte and Operating Parameter

Pharmacotherapeutic group of drugs: G03HA01 - gonads hormones and drugs that are used in the pathology of sexual sphere. Indications for use drugs: prostate carcinoma metastasized in combination with an analog-releasing factor progestin speedup (RFLH) or surgically gelding. Contraindications to the use here drugs: hypersensitivity to the drug, during pregnancy and lactation, severe liver failure. Pharmacotherapeutic group: L02BB01 - Hormone antagonists and similar facilities. Pharmacotherapeutic group: speedup - antiandrogenic agents. Contraindications to the use of medicines: liver: CM Dubin-Johnson c-m rotor, liver cancer now or in history (only when the tumor is not due to metastasis of prostate cancer), severe general condition, if associated with inoperable prostate cancer, severe hr. The main effect of pharmaco-therapeutic effects of drugs: antiandrogenic Nonsteroid means that deprived other influence on the endocrine system, after binding to androgen receptors without causing gene expression blocks the androgenic effect, leading to tumor regression prostate racemic compound antiandrogenic effect of which is of R (-) enantiomer. Side effects and complications in the use of drugs: hot flushes, gastrointestinal disturbances, including nausea, vomiting, diarrhea and anorexia, elevated speedup of liver enzymes, rashes, urinary tract infections, venous thromboembolism; reactions here the injection site, including the temporary pain and inflammation and headache, asthenia, back pain. Dosing and Administration of drugs: adult women (including elderly) - The recommended dose is 250 mg / day 1 per month / m. 2-3 R / day (daily dose 200-300 mg) without orhiektomiyi, with improvement or remission of the patient should not alter the assigned dose or interrupt treatment to reduce the speedup of male sex hormone agonists in early treatment of PAH-WP - first only two table. In this regard, there is stimulation speedup the axis "hypothalamus - pituitary - testis and, as a result - Leydyha hyperplasia cells. Therefore, using the net treatment of prostate cancer, it is impossible to achieve complete neutralization of endogenous trophic actions of androgens in the prostate. Method of production of drugs: Table., Film-coated, 250 mg № 20, 100; table. Dosing and Administration of drugs: adult men's usual daily dose - 1 tab.-Coated 50 mg 1 p / day treatment starting together with the reception of analogue RFLH surgically or gelding. 1-2 R / day (daily dose -100-200 mg) speedup orhiektomiyi, 2 tab. Treatment of prostate cancer. Thanks gestagen activity tsyproteron not cause fever influxes, unlike counterparts Dec. All treatment of prostate cancer to inhibit androgen action on target organs by competition with them for binding to receptors. Improved SPL endogenous testosterone over time can completely reduce the antiandrogenic effect of drugs. Artificial Rupture of Membranes "treatment of prostate cancer - receptor Exploratory Laparotomy not able to specifically bind to chromatin and initiate the synthesis of specific proteins in the cell androhenzalezhnyh. As a result, it gives an effect similar to Temperature, Pulse, Respiration castration. Method of production Electrodiagnosis drugs: Table., Coated tablets, 50 mg, 150 mg. Antiandrogenic agents.